JP2003503042A - ｉＣＥ遺伝子のシフトされたＯＲＦ由来のペプチド化合物 - Google Patents

ｉＣＥ遺伝子のシフトされたＯＲＦ由来のペプチド化合物

Info

Publication number
JP2003503042A
JP2003503042A JP2001506778A JP2001506778A JP2003503042A JP 2003503042 A JP2003503042 A JP 2003503042A JP 2001506778 A JP2001506778 A JP 2001506778A JP 2001506778 A JP2001506778 A JP 2001506778A JP 2003503042 A JP2003503042 A JP 2003503042A
Authority
JP
Japan
Prior art keywords
sequence
peptide
peptide compound
cells
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001506778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003503042A5 (https=
Inventor
ロンザン、クリストフ
スコット、ベロニク
トリエベル、フレデリック
Original Assignee
アンスティテュ・ギュスタブ−ルウシイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンスティテュ・ギュスタブ−ルウシイ filed Critical アンスティテュ・ギュスタブ−ルウシイ
Publication of JP2003503042A publication Critical patent/JP2003503042A/ja
Publication of JP2003503042A5 publication Critical patent/JP2003503042A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2001506778A 1999-06-28 2000-06-27 ｉＣＥ遺伝子のシフトされたＯＲＦ由来のペプチド化合物 Pending JP2003503042A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR99/08224 1999-06-28
FR9908224A FR2795415B1 (fr) 1999-06-28 1999-06-28 Compose peptidique derive d'une orf decalee du gene ice
PCT/FR2000/001791 WO2001000784A2 (fr) 1999-06-28 2000-06-27 COMPOSE PEPTIDIQUE DERIVE D'UNE ORF DECALEE DU GENE iCE

Publications (2)

Publication Number Publication Date
JP2003503042A true JP2003503042A (ja) 2003-01-28
JP2003503042A5 JP2003503042A5 (https=) 2008-04-03

Family

ID=9547371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001506778A Pending JP2003503042A (ja) 1999-06-28 2000-06-27 ｉＣＥ遺伝子のシフトされたＯＲＦ由来のペプチド化合物

Country Status (9)

Country Link
US (1) US6875844B1 (https=)
EP (1) EP1192179B1 (https=)
JP (1) JP2003503042A (https=)
AT (1) ATE309265T1 (https=)
AU (1) AU5992500A (https=)
CA (1) CA2377433A1 (https=)
DE (1) DE60023891T2 (https=)
FR (1) FR2795415B1 (https=)
WO (1) WO2001000784A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535598A (ja) * 2013-11-08 2016-11-17 グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス，チャイニーズ アカデミー オブ サイエンスィズ 哺乳類細胞内に外来性ミトコンドリアを導入するための方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
US7597894B2 (en) 2003-03-05 2009-10-06 Dendreon Corporation Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
WO2018035311A1 (en) * 2016-08-19 2018-02-22 Gray John T Compositions and methods for modulating gene expression using reading frame surveillance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505650A (ja) * 1996-02-08 2000-05-16 アメリカ合衆国 樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物
AU7724398A (en) * 1997-06-06 1998-12-21 Regents Of The University Of California, The A melanoma associated antigen, t cell epitopes thereof and methods of using sa me
AU9572098A (en) * 1997-10-08 1999-04-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Novel human cancer antigen ny eso-1/cag-3 and gene encoding same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010022212, Ｂｉｏｃｈｅｍｉｃａｌ ａｎｄ Ｂｉｏｐｈｙｓｉｃａｌ Ｒｅｓｅａｒｃｈ Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ, 1997, Ｖｏｌ．２３３, ｐ．１１７−１２０ *
JPN6010022213, Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｂｉｏｃｈｅｍｉｃａｌ Ｃｈｅｍｉｓｔｒｙ, 1997, Ｖｏｌ．２７２， Ｎｏ．２３, ｐ．１４７６９−１４７７５ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535598A (ja) * 2013-11-08 2016-11-17 グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス，チャイニーズ アカデミー オブ サイエンスィズ 哺乳類細胞内に外来性ミトコンドリアを導入するための方法

Also Published As

Publication number Publication date
US6875844B1 (en) 2005-04-05
WO2001000784A3 (fr) 2001-07-26
EP1192179B1 (fr) 2005-11-09
AU5992500A (en) 2001-01-31
WO2001000784A2 (fr) 2001-01-04
FR2795415A1 (fr) 2000-12-29
DE60023891T2 (de) 2006-07-27
EP1192179A2 (fr) 2002-04-03
DE60023891D1 (de) 2005-12-15
ATE309265T1 (de) 2005-11-15
CA2377433A1 (fr) 2001-01-04
FR2795415B1 (fr) 2003-09-05

Similar Documents

Publication Publication Date Title
Ronsin et al. A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ
Bruggen et al. Autologous cytolytic T lymphocytes recognize a MAGE‐1 nonapeptide on melanomas expressing HLA‐Cw* 1601
Bloom et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
van der Bruggen et al. Tumor antigens recognized by T lymphocytes
JP3998713B2 (ja) チロシナーゼ関連タンパク質１及び２のヒト癌抗原並びにこれをコードする遺伝子
JP3759738B2 (ja) 免疫原性ペプチド
AU749544B2 (en) Tumor antigen peptides originating in cyclophilin B
JP4900884B2 (ja) 腫瘍抗原
AU762903B2 (en) Mutated peptide compounds, derived from hsp70, useful in cancer immunotherapy
EP1021535B1 (en) Human cancer antigen ny eso-1/cag-3 and gene encoding same
KR20010024585A (ko) 종양-특이적 항원, 이들의 제조방법, 및 이들의 면역화 및진단에서의 용도
US5843648A (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
JP2010029194A (ja) 新規な腫瘍抗原タンパク質ｓａｒｔ−３、およびその腫瘍抗原ペプチド
JP3721437B2 (ja) 単離チロシナーゼ由来ペプチド抗原とその利用方法
JP2003503042A (ja) ｉＣＥ遺伝子のシフトされたＯＲＦ由来のペプチド化合物
JP2004535779A (ja) ヒトｍｄｍ２プロト腫瘍遺伝子より製造される腫瘍ペプチド抗原
JPWO2001011044A1 (ja) 腫瘍抗原
JPWO2000012701A1 (ja) 新規な腫瘍抗原タンパク質ｓａｒｔ−３、およびその腫瘍抗原ペプチド
US7084239B1 (en) Cancer peptides of NY-ESO-1/CAG-3
US20050025754A1 (en) Increased T-cell tumor infiltration by mutant light
WO2000032770A1 (fr) Nouvelle proteine d'antigene tumoral art-1 et peptide d'antigene tumoral de cette derniere
Vantomme et al. A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16
US7001600B1 (en) Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
EP1806403A2 (en) Human cancer antigen NY ESO 1/CAG-3 and gene encoding same
EP1562622A2 (en) Immunogenic epitopes for fibroblast growth factor 5 (fgf-5) presented by hla-a3 and hla-a2

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101005